Patient access schemes (PAS) – process revision

From November 2020 our process has changed to align the arrangements for Patient Access Schemes (PAS) across all submissions.

Companies can now submit a PAS or offer an improved PAS for all submissions following the New Drugs Committee meeting. Previously this only applied to submissions for medicines eligible for a Patient and Clinician Engagement (PACE) meeting ( This change encompasses both simple and complex schemes.

More information can be found in the ‘Guidance to submitting companies for completion of the New Product Assessment Form (NPAF)’.

Back to latest updates